37 completed, 12 recruiting, 9 unknown, 6 terminated. 32 Phase 2, 30 Phase 1, 7 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Antibodies, Monoclonal: new trials by email Literature Review of Antibodies, Monoclonal trials Research Report on Antibodies, Monoclonal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Horizon Two: HR NDMM (MMRC-100) Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant - High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Recruiting | Multiple Myeloma Research Consortium | 300 | 2026-04-30 | 2026-10-02 |
| Comparison of Two Methods of Immunoprophylaxis Against RSV in Term Newborns to compare vaccine and monoclonal antibody - Bronchiolitis | Completed | Jean-Michel HASCOET | 1137 | 2025-09-01 | 2026-10-21 | |
| Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents) - Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | Completed | Sanofi | 4006 | 2025-07-15 | 2026-09-11 | |
| Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody - Multiple Myeloma, Relapsed, Multiple Myeloma (MM) | Recruiting | Sung-Soo Park | 174 | 2025-07-14 | 2025-07-15 | |
| ALPINE: Maintenance Letrozole/Abemaciclib Abemaciclib, Letrozole, Pembrolizumab - Endometrial Cancer, Recurrent Endometrial Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-09-25 | 2026-10-15 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| Immunotherapy in Lymphoma CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma | Recruiting | Sung-Soo Park | 72 | 2024-06-26 | 2025-01-28 | |
| A Study of BND-35 in Participants With Advanced Solid Tumors BND-35, Nivolumab, Cetuximab - Cancer | Phase 1 | Terminated | Biond Biologics | 12 | 2024-06-02 | 2026-06-18 |
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer Pentoxifylline, FOLFOX, XELOX - Metastatic Colorectal Carcinoma | Phase 4 | Completed | Tanta University | 44 | 2024-02-01 | 2026-10-21 |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers IMC-R117C, Chemotherapy drug, Kinase inhibitor - Cancer, HLA-A*02:01-positive | Phase 1 / Phase 2 | Recruiting | Immunocore Ltd | 600 | 2024-01-10 | 2026-01-28 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics Biotechnologies GmbH | 400 | 2023-08-09 | 2026-09-01 |
| Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer Biopsy, FOLFIRINOX, Ciprofloxacin - Pancreatic Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 25 | 2023-03-16 | 2024-10-15 |
| Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer Nituzumab, Serplulimab - Cervical Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 37 | 2023-02-01 | 2024-06-12 |
| 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) 3BNC117-LS, 10-1074-LS, N803 - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 28 | 2022-12-07 | 2026-03-31 |
| Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 Ivermectin - Covid19, COVID-19 Pneumonia | Unknown | Patrick Robinson | 1000 | 2022-05-01 | 2022-04-27 | |
| IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. IBI376, Rituximab - Inert Non Hodgkin's Lymphoma | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2021-12-31 | 2023-05-12 |
| COVID-19 International Drug Pregnancy Registry Antiviral Agents, Monoclonal antibody - Covid19 | Recruiting | Pregistry | 2000 | 2021-12-01 | 2025-09-26 | |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Monoclonal antibody (Mab) sB24M - Pyoderma, Pyoderma Gangrenosum | Early Phase 1 | Completed | SWISS BIOPHARMA MED GmbH | 10 | 2021-05-24 | 2023-03-20 |
| 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals 3BNC117-LS, 10-1074-LS - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 6 | 2020-10-13 | 2023-06-26 |
Showing 20 of 73. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (7) · Breast Neoplasms (5) · Lymphoma, Follicular (5) · COVID-19 (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Neoplasm Metastasis (4) · Neoplasms (4) · Recurrence (4) · Burkitt Lymphoma (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large B-Cell, Diffuse (3) · Melanoma (3) · Pancreatic Neoplasms (3) · Waldenstrom Macroglobulinemia (3)
Rockefeller University (7) · Biogen (2) · Dana-Farber Cancer Institute (2) · GlaxoSmithKline (2) · Immunocore Ltd (2) · Sung-Soo Park (2) · AIDS Malignancy Consortium (1) · Abbott (1) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Barbara Ann Karmanos Cancer Institute (1) · Bayer (1) · Beth Christian (1) · Biond Biologics (1) · Bristol-Myers Squibb (1)
United States (44) · Germany (9) · United Kingdom (7) · Netherlands (6) · France (5) · Italy (5) · Spain (5) · Australia (4) · Canada (4) · South Korea (4) · Belgium (3) · Brazil (3) · Austria (2) · China (2) · Denmark (2)
Marina Caskey, MD (6) · Ajay Nooka, MD, MPH (1) · Alan S. Wayne, MD (1) · Alexandra M. Levine, MD (1) · Amit Shah, M.D. (1) · Anil Tulpule, MD (1) · Anthony Atala, MD (1) · Beth Christian, MD (1) · Cheryl Renz, MD (1) · Christos Fountzilas (1) · Dalia Refaat, Assistant Professor (1) · Darcy V Spicer, MD (1)
PMID 32838558, PMID 11919489, PMID 12232843, PMID 12559647, PMID 18536599, PMID 18695118, PMID 20525992, PMID 21323540, PMID 21436454, PMID 22694829, PMID 23400564, PMID 23444228, PMID 23942774, PMID 24124874, PMID 24618589, PMID 25103848, PMID 25214238, PMID 25649350, PMID 25667295, PMID 25847298, PMID 26627641, PMID 26700304, PMID 27241619, PMID 30760509, PMID 31042791, PMID 32221013, PMID 32615072, PMID 33227231, PMID 33234158, PMID 33278625, PMID 33293006, PMID 33389725, PMID 34871104, PMID 35544074, PMID 35880940, PMID 36705924, PMID 36803992, PMID 37188783, PMID 37470445, PMID 37778363, PMID 37973784, PMID 38225598, PMID 38677300, PMID 39896880, PMID 41082886, PMID 41321979, PMID 41459482, PMID 41793309, PMID 9400786
U01AI145921 (2), 2009 (1), 2014 (1), 2016 (1), 2017 (1), 2023 (1), P30CA014089 (1), P30CA016056 (1), P30CA124435 (1), P30CA138292 (1)